BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 26497923)

  • 1. The Impact of Adding Taxanes to Gemcitabine and Platinum Chemotherapy for the First-Line Therapy of Advanced or Metastatic Urothelial Cancer: A Systematic Review and Meta-analysis.
    Giannatempo P; Pond GR; Sonpavde G; Raggi D; Naik G; Galsky MD; Bellmunt J; Necchi A
    Eur Urol; 2016 Apr; 69(4):624-633. PubMed ID: 26497923
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Single-agent Taxane Versus Taxane-containing Combination Chemotherapy as Salvage Therapy for Advanced Urothelial Carcinoma.
    Sonpavde G; Pond GR; Choueiri TK; Mullane S; Niegisch G; Albers P; Necchi A; Di Lorenzo G; Buonerba C; Rozzi A; Matsumoto K; Lee JL; Kitamura H; Kume H; Bellmunt J
    Eur Urol; 2016 Apr; 69(4):634-641. PubMed ID: 26264159
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and Safety of Gemcitabine Plus Either Taxane or Carboplatin in the First-Line Setting of Metastatic Urothelial Carcinoma: A Systematic Review and Meta-Analysis.
    Necchi A; Pond GR; Raggi D; Giannatempo P; Vogelzang NJ; Grivas P; Galsky MD; Bellmunt J; Sonpavde G
    Clin Genitourin Cancer; 2017 Feb; 15(1):23-30.e2. PubMed ID: 27324051
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Double-blind, randomized trial of docetaxel plus vandetanib versus docetaxel plus placebo in platinum-pretreated metastatic urothelial cancer.
    Choueiri TK; Ross RW; Jacobus S; Vaishampayan U; Yu EY; Quinn DI; Hahn NM; Hutson TE; Sonpavde G; Morrissey SC; Buckle GC; Kim WY; Petrylak DP; Ryan CW; Eisenberger MA; Mortazavi A; Bubley GJ; Taplin ME; Rosenberg JE; Kantoff PW
    J Clin Oncol; 2012 Feb; 30(5):507-12. PubMed ID: 22184381
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II trial of combination nab-paclitaxel, carboplatin and gemcitabine in first line therapy of advanced urothelial carcinoma.
    Alva A; Daignault S; Smith DC; Hussain M
    Invest New Drugs; 2014 Feb; 32(1):188-94. PubMed ID: 24318901
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gemcitabine and docetaxel, an effective second-line chemotherapy for lung metastasis of urothelial carcinoma.
    Naiki T; Kawai N; Hashimoto Y; Okamura T; Ando R; Yasui T; Okada A; Etani T; Tozawa K; Kohri K
    Int J Clin Oncol; 2014; 19(3):516-22. PubMed ID: 23749066
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Sequential Treatment of Advanced Squamous Lung Cancer: 
First-line Gemcitabine +/- platinum Followed by Second-line Taxanes +/- platinum Versus Reverse Sequence].
    Xu J; Liu X; Gao H; Guo W; Tang C; Li X; Li J; Qin H; Wang W; Qu L; Wang H; Yang H; Yang L
    Zhongguo Fei Ai Za Zhi; 2015 May; 18(5):308-14. PubMed ID: 25975302
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial.
    Powles T; van der Heijden MS; Castellano D; Galsky MD; Loriot Y; Petrylak DP; Ogawa O; Park SH; Lee JL; De Giorgi U; Bögemann M; Bamias A; Eigl BJ; Gurney H; Mukherjee SD; Fradet Y; Skoneczna I; Tsiatas M; Novikov A; Suárez C; Fay AP; Duran I; Necchi A; Wildsmith S; He P; Angra N; Gupta AK; Levin W; Bellmunt J;
    Lancet Oncol; 2020 Dec; 21(12):1574-1588. PubMed ID: 32971005
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gemcitabine and docetaxel as first-line treatment for advanced urothelial carcinoma: a phase II study.
    Ardavanis A; Tryfonopoulos D; Alexopoulos A; Kandylis C; Lainakis G; Rigatos G
    Br J Cancer; 2005 Feb; 92(4):645-50. PubMed ID: 15685232
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial.
    Patel MR; Ellerton J; Infante JR; Agrawal M; Gordon M; Aljumaily R; Britten CD; Dirix L; Lee KW; Taylor M; Schöffski P; Wang D; Ravaud A; Gelb AB; Xiong J; Rosen G; Gulley JL; Apolo AB
    Lancet Oncol; 2018 Jan; 19(1):51-64. PubMed ID: 29217288
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II trial of first-line chemotherapy with gemcitabine, etoposide, and cisplatin for patients with advanced urothelial carcinoma.
    Urakami S; Fujii Y; Yamamoto S; Yuasa T; Kitsukawa S; Sakura M; Yano A; Saito K; Masuda H; Yonese J; Fukui I
    Urol Oncol; 2014 Jan; 32(1):35.e1-7. PubMed ID: 23562233
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination therapy consisting of gemcitabine, carboplatin, and docetaxel as an active treatment for advanced urothelial carcinoma.
    Tsuruta H; Inoue T; Narita S; Horikawa Y; Saito M; Obara T; Numakura K; Maita S; Satoh S; Tsuchiya N; Habuchi T
    Int J Clin Oncol; 2011 Oct; 16(5):533-8. PubMed ID: 21431341
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of efficacy and toxicity of second-line combination chemotherapy regimens in patients with advanced urothelial carcinoma.
    Takeyama Y; Kato M; Nishihara C; Yamasaki T; Iguchi T; Tamada S; Kuratsukuri K; Nakatani T
    Int J Clin Oncol; 2018 Oct; 23(5):944-950. PubMed ID: 29785621
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial.
    Powles T; Csőszi T; Özgüroğlu M; Matsubara N; Géczi L; Cheng SY; Fradet Y; Oudard S; Vulsteke C; Morales Barrera R; Fléchon A; Gunduz S; Loriot Y; Rodriguez-Vida A; Mamtani R; Yu EY; Nam K; Imai K; Homet Moreno B; Alva A;
    Lancet Oncol; 2021 Jul; 22(7):931-945. PubMed ID: 34051178
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gemcitabine and docetaxel as second-line chemotherapy for patients with nonsmall cell lung carcinoma who fail prior paclitaxel plus platinum-based regimens.
    Kosmas C; Tsavaris N; Vadiaka M; Stavroyianni N; Koutras A; Malamos N; Onyenadum A; Rokana S; Polyzos A; Kalofonos HP
    Cancer; 2001 Dec; 92(11):2902-10. PubMed ID: 11753965
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gemcitabine plus docetaxel as first-line biweekly therapy in locally advanced and/or metastatic urothelial carcinoma: a phase II study.
    Neri B; Vannini L; Giordano C; Grifoni R; Pantaleo P; Baldazzi V; Crisci A; Lapini A; Raugei A; Carini M
    Anticancer Drugs; 2007 Nov; 18(10):1207-11. PubMed ID: 17893522
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic factors in second-line treatment of urothelial cancers with gemcitabine and paclitaxel (German Association of Urological Oncology trial AB20/99).
    Niegisch G; Fimmers R; Siener R; Park SI; Albers P;
    Eur Urol; 2011 Nov; 60(5):1087-96. PubMed ID: 21839579
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC Intergroup Study 30987.
    Bellmunt J; von der Maase H; Mead GM; Skoneczna I; De Santis M; Daugaard G; Boehle A; Chevreau C; Paz-Ares L; Laufman LR; Winquist E; Raghavan D; Marreaud S; Collette S; Sylvester R; de Wit R
    J Clin Oncol; 2012 Apr; 30(10):1107-13. PubMed ID: 22370319
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Treatment and prognosis of 117 patients with advanced urothelial carcinoma of the bladder].
    Song Y; Yang L; Zhou A; Chi Y; Wang J
    Zhonghua Zhong Liu Za Zhi; 2014 Mar; 36(3):212-6. PubMed ID: 24785283
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II trial of gemcitabine and docetaxel in patients with advanced carcinoma of the urothelium: a trial of the Eastern Cooperative Oncology Group.
    Dreicer R; Manola J; Schneider DJ; Schwerkoske JF; George CS; Roth BJ; Wilding G;
    Cancer; 2003 Jun; 97(11):2743-7. PubMed ID: 12767086
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.